Can-Fite BioPharma Ltd. (CANF)
Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, the company develops commercial predictive biomarker blood test kit for A3AR.
Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
| Country | IL |
| IPO Date | Nov 6, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Motti Farbstein |
Contact Details
Address: 10 Bareket Street Petah Tikva, IL | |
| Website | https://www.canfite.com |
Stock Details
| Ticker Symbol | CANF |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001536196 |
| CUSIP Number | 13471N201 |
| ISIN Number | US13471N3008 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Motti Farbstein | Chief Executive Officer and Chief Financial & Operating Officer |
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer & Executive Chairperson |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board & Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 17, 2025 | 6-K | Filing |
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 15, 2025 | 424B5 | Filing |
| Apr 15, 2025 | 6-K | Filing |
| Apr 14, 2025 | 6-K | Filing |
| Apr 14, 2025 | POS AM | Filing |
| Apr 14, 2025 | 6-K | Filing |
| Apr 14, 2025 | 6-K | Filing |
| Apr 14, 2025 | 20-F | Filing |